These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31760102)

  • 61. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
    Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH
    Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
    van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
    Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys.
    Kaneda K; Tachibana Y; Imanishi M; Kita H; Shigemoto R; Nambu A; Takada M
    Eur J Neurosci; 2005 Dec; 22(12):3241-54. PubMed ID: 16367790
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT.
    Bentea E; Sconce MD; Churchill MJ; Van Liefferinge J; Sato H; Meshul CK; Massie A
    Neurosci Lett; 2015 Apr; 593():1-6. PubMed ID: 25766755
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
    Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
    Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.
    Pietracupa S; Martin-Bastida A; Piccini P
    Neurol Sci; 2017 Dec; 38(12):2095-2101. PubMed ID: 28866787
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells.
    German DC; Manaye KF; Sonsalla PK; Brooks BA
    Ann N Y Acad Sci; 1992 May; 648():42-62. PubMed ID: 1353337
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A quantitative approach to developing Parkinsonian monkeys (Macaca fascicularis) with intracerebroventricular 1-methyl-4-phenylpyridinium injections.
    Li H; Lei X; Huang B; Rizak JD; Yang L; Yang S; Wu J; Lü L; Wang J; Yan T; Li H; Wang Z; Hu Y; Le W; Deng X; Li J; Xu L; Zhang B; Hu X
    J Neurosci Methods; 2015 Aug; 251():99-107. PubMed ID: 26003862
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
    Wang C; Fan G; Xu K; Wang S
    Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B; Hoyer D; Grégoire L; Morissette M; Gasparini F; Gomez-Mancilla B; Di Paolo T
    Neuroscience; 2010 Jun; 167(4):1160-7. PubMed ID: 20303391
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Changes in the rates of the tricarboxylic acid (TCA) cycle and glutamine synthesis in the monkey brain with hemiparkinsonism induced by intracarotid infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): studies by non-invasive 13C-magnetic resonance spectroscopy.
    Kanamatsu T; Otsuki T; Tokuno H; Nambu A; Takada M; Okamoto K; Watanabe H; Umeda M; Tsukada Y
    Brain Res; 2007 Nov; 1181():142-8. PubMed ID: 17919469
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
    Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.
    Pain S; Gochard A; Bodard S; Gulhan Z; Prunier-Aesch C; Chalon S
    Exp Toxicol Pathol; 2013 Jul; 65(5):689-94. PubMed ID: 23083629
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.
    Gerhardt GA; Cass WA; Huettl P; Brock S; Zhang Z; Gash DM
    Brain Res; 1999 Jan; 817(1-2):163-71. PubMed ID: 9889359
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
    Wang QM; Xu YY; Liu S; Ma ZG
    Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.
    Barcia C; Sánchez Bahillo A; Fernández-Villalba E; Bautista V; Poza Y Poza M; Fernández-Barreiro A; Hirsch EC; Herrero MT
    Glia; 2004 May; 46(4):402-9. PubMed ID: 15095370
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility.
    Martin-Bastida A; Lao-Kaim NP; Loane C; Politis M; Roussakis AA; Valle-Guzman N; Kefalopoulou Z; Paul-Visse G; Widner H; Xing Y; Schwarz ST; Auer DP; Foltynie T; Barker RA; Piccini P
    Eur J Neurol; 2017 Feb; 24(2):357-365. PubMed ID: 27982501
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.
    Masilamoni GJ; Groover O; Smith Y
    Neurobiol Dis; 2017 Apr; 100():9-18. PubMed ID: 28042095
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
    Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
    Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls.
    Taylor JR; Elsworth JD; Roth RH; Sladek JR; Collier TJ; Redmond DE
    Exp Brain Res; 1991; 85(2):335-48. PubMed ID: 1893983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.